Corbin A Helis1, Shih-Ni Prim2, Christina K Cramer2, Roy Strowd3, Glenn J Lesser4, Jaclyn J White5, Stephen B Tatter5, Adrian W Laxton5, Christopher Whitlow6, Hui-Wen Lo7, Waldemar Debinski7, James D Ververs2, Paul J Black2, Michael D Chan2. 1. Department of Radiation Oncology, Fort Belvoir Community Hospital, Fort Belvoir, Virginia, USA. 2. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 3. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 4. Department of Medicine (Hematology and Oncology), Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 5. Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 6. Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 7. Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Abstract
Background: Re-irradiation for recurrent gliomas is a controversial treatment option with no clear standard dose or concurrent systemic therapy. Methods: This series represents a single-institution retrospective review of patients treated with re-irradiation for recurrent high-grade glioma. After 2012, patients were commonly offered concurrent bevacizumab as a cytoprotective agent against radiation necrosis. Kaplan-Meier method was used to estimate overall survival and progression-free survival. Cox proportional hazards regression was used to identify factors associated with overall survival and progression-free survival. Results: Between 2001 and 2021, 52 patients underwent re-irradiation for a diagnosis of recurrent high-grade glioma. 36 patients (69.2%) had a histologic diagnosis of glioblastoma at the time of re-irradiation. The median BED10 (biological equivalent dose 10 Gy) of re-irradiation was 53.1 Gy. Twenty-one patients (40.4%) received concurrent bevacizumab with re-irradiation. Median survival for the entire cohort and for glioblastoma at the time of recurrence patients was 6.7 months and 6.0 months, respectively. For patients with glioblastoma at the time of recurrence, completing re-irradiation (HR 0.03, P < .001), use of concurrent bevacizumab (HR 0.3, P = .009), and the BED10 (HR 0.9, P = .005) were predictive of overall survival. Nine patients developed grade 3-5 toxicity; of these, 2 received concurrent bevacizumab and 7 did not (P = .15). Conclusion: High dose re-irradiation with concurrent bevacizumab is feasible in patients with recurrent gliomas. Concurrent bevacizumab and increasing radiation dose may improve survival in patients with recurrent glioblastoma. Published by Oxford University Press 2022.
Background: Re-irradiation for recurrent gliomas is a controversial treatment option with no clear standard dose or concurrent systemic therapy. Methods: This series represents a single-institution retrospective review of patients treated with re-irradiation for recurrent high-grade glioma. After 2012, patients were commonly offered concurrent bevacizumab as a cytoprotective agent against radiation necrosis. Kaplan-Meier method was used to estimate overall survival and progression-free survival. Cox proportional hazards regression was used to identify factors associated with overall survival and progression-free survival. Results: Between 2001 and 2021, 52 patients underwent re-irradiation for a diagnosis of recurrent high-grade glioma. 36 patients (69.2%) had a histologic diagnosis of glioblastoma at the time of re-irradiation. The median BED10 (biological equivalent dose 10 Gy) of re-irradiation was 53.1 Gy. Twenty-one patients (40.4%) received concurrent bevacizumab with re-irradiation. Median survival for the entire cohort and for glioblastoma at the time of recurrence patients was 6.7 months and 6.0 months, respectively. For patients with glioblastoma at the time of recurrence, completing re-irradiation (HR 0.03, P < .001), use of concurrent bevacizumab (HR 0.3, P = .009), and the BED10 (HR 0.9, P = .005) were predictive of overall survival. Nine patients developed grade 3-5 toxicity; of these, 2 received concurrent bevacizumab and 7 did not (P = .15). Conclusion: High dose re-irradiation with concurrent bevacizumab is feasible in patients with recurrent gliomas. Concurrent bevacizumab and increasing radiation dose may improve survival in patients with recurrent glioblastoma. Published by Oxford University Press 2022.
Authors: Jarrod B Adkison; Wolfgang Tomé; Songwon Seo; Gregory M Richards; H Ian Robins; Karl Rassmussen; James S Welsh; Peter A Mahler; Steven P Howard Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-14 Impact factor: 7.038
Authors: Michael H Soike; Emory R McTyre; Nameeta Shah; Ralph B Puchalski; Jordan A Holmes; Anna K Paulsson; Lance D Miller; Christina K Cramer; Glenn J Lesser; Roy E Strowd; William H Hinson; Ryan T Mott; Annette J Johnson; Hui-Wen Lo; Adrian W Laxton; Stephen B Tatter; Waldemar Debinski; Michael D Chan Journal: Neuroradiology Date: 2018-08-10 Impact factor: 2.804
Authors: Wolfgang Wick; Thierry Gorlia; Martin Bendszus; Martin Taphoorn; Felix Sahm; Inga Harting; Alba A Brandes; Walter Taal; Julien Domont; Ahmed Idbaih; Mario Campone; Paul M Clement; Roger Stupp; Michel Fabbro; Emilie Le Rhun; Francois Dubois; Michael Weller; Andreas von Deimling; Vassilis Golfinopoulos; Jacoline C Bromberg; Michael Platten; Martin Klein; Martin J van den Bent Journal: N Engl J Med Date: 2017-11-16 Impact factor: 91.245
Authors: Jordan A Holmes; Anna K Paulsson; Brandi R Page; Lance D Miller; Wennuan Liu; Jianfeng Xu; William H Hinson; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Waldemar Debinski; Michael D Chan Journal: J Neurooncol Date: 2015-07-18 Impact factor: 4.130
Authors: Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-01 Impact factor: 7.038
Authors: James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Dana Greene-Schloesser; Mike E Robbins; Ann M Peiffer; Edward G Shaw; Kenneth T Wheeler; Michael D Chan Journal: Front Oncol Date: 2012-07-19 Impact factor: 6.244
Authors: Joseph Chan; Dasantha Jayamanne; Helen Wheeler; Mustafa Khasraw; Matthew Wong; Marina Kastelan; Lesley Guo; Michael Back Journal: Clin Transl Radiat Oncol Date: 2020-03-09